It has been suggested that some adult bone marrow cells (BMC) can localize to the lung and develop tissue-specific characteristics including those of pulmonary epithelial cells. Here, we show that the combination of mild airway injury (naphthalene-induced) as a conditioning regimen to direct the site of BMC localization and transtracheal delivery of short-term cultured BMC enhances airway localization and adoption of an epithelial-like phenotype. Confocal analysis of airway and alveolar-localized BMC (fluorescently-labeled) with epithelial markers show expression of the pulmonary epithelial proteins, Clara cell secretory protein and surfactant protein-C. To confirm epithelial gene expression by BMC, we generated transgenic mice expressing green fluorescent protein (GFP) driven by the epithelial-specific cytokeratin-18 promoter and injected BMC from these mice transtracheally into wild-type recipient after naphthalene-induced airway injury. BMC retention in the lung was observed to at least 120 days following cell delivery with increasing GFP transgene expression over time. Some BMC cultured in vitro over time also expressed GFP transgene suggesting epithelial transdifferentiation of the BMC. The results indicate that targeted delivery of BMC can promote airway regeneration.
Introduction
The ethical concerns of using embryonic stem cells have prompted great interest in identifying the utility of adult tissue-specific progenitor cells and bone marrow-derived stem cells for the purpose of tissue repair or regeneration. While controversial, some data suggests that adult stem cells can engraft and transdifferentiate into tissue-specific cell types of various organs such as the heart (29), pancreas (6) , and nervous system (9). This potential plasticity suggests that BMC could also be used as "cell replacement" therapy for pulmonary diseases, such as cystic fibrosis, a debilitating incurable disease that is characterized by abnormal salt and water transport leading to abnormal airway secretions, impaired mucociliary clearance, and chronic inflammation due to secondary bacterial infections (32) .
Studies have shown that bone marrow cell delivery to the injured lung promotes lung repair and regeneration (19, 31) . The common method of cell transplantation into the lung is intravenous injection by tail-vein (24, 26, 31) or jugular vein (5, 44) . However, intravenous injection may not be the optimal technique and direct cell delivery via the transtracheal route has many theoretical advantages including better efficiency of cell delivery to the airway and respiratory epithelium, reduced risk of systemic delivery, reduced requirement for tissue injury to promote cell homing. Here, we assessed the potential of short-term cultured plastic-adherent BMC using trans-tracheal cell delivery in a targeted, acute, mild, and reversible naphthaleneinduced airway injury known to specifically deplete airway Clara cells (36) . By depleting these local progenitor cells (3, 10) , we hoped to facilitate the contribution of BMC to airway regeneration. Thus, in a manner analogous to bone marrow transplantation, naphthalene was used not as a model of airway injury to be ameliorated, but as a "conditioning regimen" to create an airway-specific niche for cell incorporation.
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Our results demonstrate enhanced airway and alveolar incorporation of BMC in or on the epithelium after naphthalene-induced injury with direct transtracheal delivery compared to intravenous cell delivery. Some of the retained BMC expressed the airway epithelial markers CCSP. To further demonstrate the transdifferentiation potential of these bone marrow cells, we developed a transgenic mouse model with the human cytokeratin-18 promoter driving GFP expression. Using this animal as bone marrow donor, we demonstrated cytokeratin-18 promoterdriven transgene expression, which increased over time and persisted up to at least 120 days.
These important and novel observations suggest that the bone marrow does indeed harbor cells with the potential to contribute to airway regeneration. Moreover, using a combination of shortterm ex vivo culture, a simple and direct mode of cell delivery, and a specific mild epithelial injury, targeted incorporation of BMC to the lung epithelium can be achieved. Subsequently, these cells can differentiate to express epithelial genes.
Materials and Methods

Animals
Adult male (4-6 weeks) C57Bl/6 (Charles River Laboratories, Wilmington, MA) and transgenic K18GFP (reporter gene enhanced GFP is driven by the cytokeratin-18 promoter; CD1 background) mice were BMC donors. Recipients were strain and age-matched females (4-6 weeks). All animal procedures were approved by the University Health Network Animal Care
Committee. All mice received care in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research, and the Guide for the Care and Use of Experimental Animals formulated by the Canadian Council on Animal Care.
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Bone marrow harvest, culture and fluorescent labeling BMC were harvested as previously described(24). Briefly, whole bone marrow was harvested aseptically by flushing femurs and tibiae of donor mice with cold Dulbecco's Modified Eagle Medium (DMEM; Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1% penicillin-streptomycin (Gibco, Grand Island, NY) using a 23G needle. Bone marrow cells (BMC) were plated on standard plastic tissue culture flasks at a density of 5x10 5 
Tracheal epithelial cell isolation and culture
TEC were isolated and cultured as previously described(43). Briefly TEC were harvested by 0.15% pronase digestion overnight at 4°C followed by DNase I digestion on ice for 10 minutes.
The cells were plated on plastic culture plates for 3 hours to adhere fibroblasts. The non-adhered cell epithelial cell populations were then seeded onto collagen type IV-coated transwell membranes (Costar) and cultured for 2-3 weeks.
Naphthalene-induced lung injury and BMC administration
Female recipient mice (4-6 weeks old) were given an intraperitoneal injection of naphthalene (>99% pure; Sigma Chemical, St. Louis, MO), 200 mg per kg body weight as previously described (36) . The same dose was used for both C57Bl/6 and CD1 strains. Clara cell depletion was determined by immunoperoxidase staining for CCSP and blindly assessed by a pulmonary pathologist (DMH). BMC (10 6 cells per mouse) were delivered transtracheally or intravenously (via jugular vein) 2 days following injury. For transtracheal delivery, mice were anesthetized with 5% isofluorane and intubated. Using a pipette and sterile 100 µl volume gelloading tips, 50 µl of cell suspension was injected directly into the trachea distal to the vocal cords. The mice were then rotated to ensure equal dispersion of the cell suspension to both lungs.
For intravenous injection, mice were anesthetized (100 mg/kg ketamine and 5 mg/kg xylazine immunohistochemistry. The heart, spleen, liver, kidney and intestines were also harvested.
Whole lungs and heart from CD1 recipient mice that received K18EGFP BMC were quickly harvested and snap-frozen in liquid nitrogen.
Lung Function Measurements
Mice (n 3 per time point) were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (5 mg/kg) mixture. A tracheostomy was performed after dissection of the neck to expose the trachea. A metal cannula for mouse (1.0 mm, Harvard Apparatus Canada, St. Laurent, Canada) was inserted into the trachea, and animals were connected to a volume controlled constant flow ventilator (Inspira Advanced Safety Ventilator, Harvard Apparatus).
Anaesthesia was continuously maintained with isoflurane and body temperature was maintained at 37°C by an immersion thermostat throughout the experiment. The animals were then ventilated for 20 minutes with a tidal volume of 5 ml/kg, an inspired oxygen fraction of 1.0, an inspiratory/expiratory ratio 1:2 and a frequency of 140 breaths/min. An esophageal catheter (Harvard Apparatus) was inserted for measurement of dynamic lung compliance. Airway pressures and dynamic lung compliance were continuously monitored throughout the 20 minute period of mechanical ventilation (MV) with HSE-USB acquisition hardware and Pulmodyn software (H. Sachs Elektronik, March-Hugstetten, Germany). 
Assessment of donor cells in recipient lungs
Generation and characterization of K18GFP transgenic mice
The K18mTE-EGFP was constructed from the K18mTELacZ expression construct (7). It contains 3.4kb regulatory elements consisting of the 2.5 kb 5' flanking sequence of human K18, including the native promoter, followed by K18 intron 1, and the alfalfa mosaic virus translational enhancer (TE) sequence (20). The coding sequence of pEGFP-N1 (Clontech) was inserted immediately after TE sequence. At the 3' end of the EGFP coding sequence, the 1.8 kb 3' untranslated region (UTR) of human K18 was inserted to replace the SV40 small T antigen intron and SV40 early polyA signal of the K18mTELacZ. The K18mTE-EGFP cassette was purified as a 6.1 kb fragment, including the regulatory elements, EGFP coding sequence, and the 3' UTR from K18. Transgenic mice were generated with CD1 mice by standard microinjection procedures. Founder mice were identified by polymerase chain reaction (PCR) and Southern blot analysis. F1 animals were obtained by breeding founder mice with wild-type CD1 mice.
Localization of cytokeratin-18 promoter-driven GFP expression in the tissues was enhanced by staining with anti-GFP (1:500; Abcam) and visualized with AlexaFluor-488 secondary immunoglobulin. TEC and BMC from K18GFP and wild-type mice were seeded and fixed with 4% PFA on slide chambers for immunostaining with anti-GFP antibody using method described above. Non-specific binding was determined with isotype controls.
Real-time PCR analysis
To quantify bone marrow cell in the lungs, excised female lungs were spiked with 10 Total RNA was prepared from TEC, fibroblasts and BMC (n 3 sets of BMC from different animals) from K18GFP mice using the RNeasy Kit (Qiagen, Valencia, CA). 1 µg of RNA was reverse transcribed for first-strand cDNA using Superscript II (Sigma) according to manufacturer's protocol. Real-time PCR (SYBR green detection method; Applied Biosystems, Foster City, CA) was performed for amplification of K18GFP expression using the above primers.
GAPDH was determined to be the most stable house-keeping gene by geNorm program therefore it was used as the housekeeping gene to normalize gene expression levels using REST-384 (relative expression software tool, available at www.Gene-Quantification.info) program. The real-time PCR conditions and instrumentation were as follows: 50°C for 2 min; 95°C for 10 min;
35 cycles at 94°C for 15 sec; 60°C for 1 min followed by dissociation using the ABI7900HT robot and analyzed with SDS 2.0 software.
Flow Cytometry
Freshly isolated BMC and plastic-adherent BMC (cultured for 7 days, 5 
Statistical Analysis
Data are presented as mean ± SEM. Statistical comparisons between time points were done by one-way analysis of variance (ANOVA) followed by Tukey's post-hoc tests (Prism 4.0).
Paired t-tests were performed to compare fresh and cultured BMC and transtracheal and intravenous delivery. For all tests, statistical significance was defined as p<0.05.
Results
To determine whether short-term plastic-adherent BMC could repopulate the airway epithelium, we chose to assess the potential of BMC cultured on plastic for 7 days. The phenotype of these BMC was characterized using flow cytometric analysis with a panel of bone marrow cell markers including CD34, CD44, CD45, CD90, CD105, CD106, Type IV Collagen, vimentin and Sca-1 (Fig. 1) . A large percentage of the BMC were positive for the stem cell marker Sca-1 (50.37 ± 0.63%). Small populations of CD34 positive (1.23 ± 0.26%) and CD45 positive (15.45 ± 3.38%) cells were also found. A larger percentage of BMC were positive for (10.73 ± 0.9%), a marker of mesenchymal stromal cells but were essentially negative for other mesenchymal cell markers; CD90 (0.47 ± 0.23%), CD106 (0.57 ± 0.12%) and vimentin (0%).
Mild airway injury promotes BMC deposition
In order to replace cells in the airway epithelium, we reasoned that injury to the native airway would be required. Naphthalene has been reported to selectively injure the Clara cells of the bronchiolar epithelium, in a reversible fashion (36) . In our studies, naphthalene specifically but transiently depleted the airway Clara cell population from as early as 2 days following injury up to 20 days (Fig. S1 ). This mild and reversible injury did not significantly alter lung function (Table S2 ). All mice recovered without mortality.
We chose to administer cells 2 days following naphthalene injection. Fluorescentlylabeled BMC were delivered trans-tracheally into naphthalene-injured and vehicle-treated (uninjured) C57Bl/6 mice. CMTMR-labeled BMC were easily detected in the distal airways and alveoli of naphthalene-injured lungs ( Fig. 2A,B) . In the absence of injury, no donor BMC were detected (Fig. 2C,D) confirming that injury is required for BMC retention. We observed no difference in donor BMC levels in the lungs of mice that received BMC 2 or 5 days after naphthalene injection (data not shown).
CMTMR-labeled BMC were observed in or on the injured epithelium as early as 1 day following cell delivery and these cells persisted for at least 14 days thereafter. Quantification of CMTMR-labeled BMC in the lungs showed up to 4 CMTMR + cell per 100 nuclei in the central sections of the lung as early as 1 day following cell delivery, which declined to about 2.5 cell per SRY gene detected up to 7.5x10 6 (~75%) of the 10 6 male BMC in both lungs after 1 day of cell delivery and decreased to 10 5 cells by 14 days. (Fig. 2F ).
Transtracheal cell delivery enhances BMC deposition
The lung is a unique organ in which therapeutic reagents can be delivered directly to the organ through the airway for targeted therapy. To determine if the airway might be a more effective route for cell delivery, we compared transtracheal to intravenous injections of BMC.
Two days following naphthalene injury, 10 6 CMTMR-labeled BMC were injected transtracheally or intravascularly -into the jugular vein of naphthalene-injured mice. One day following cell delivery, fluorescent microscopic examination demonstrated significantly more cells in the lungs following direct transtracheal delivery than following intravenous delivery (Fig. 2G ). The number of cells detected in lungs after transtracheal delivery was 4-fold greater than intravenous delivery (Fig. 2H, p<0 .001). Following transtracheal delivery, BMC could be found in the airway, while following intravenous administration the majority of the cells were seen in the lung parenchyma itself. In addition, transtracheal delivery proved to be more specific to the lung. Real time PCR assessment for the SRY gene detected up to 5x10 4 male BMC in the right lung after 14 days of transtracheal cell delivery (Fig. 2I) . Intravenous delivery yielded 10-fold less cells compared to transtracheal. Donor BMC were observed in the recipient liver, spleen and bone marrow in animals that received intravenous delivery, but no cells were seen in these sites after transtracheal delivery of the cells (data not shown).
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BMC found in the lung express lung epithelial markers
To determine whether these BMC can adopt a phenotype similar to lung epithelium, we assessed for co-localization of CMTMR-labeled BMC with airway epithelial marker CCSP.
Immunofluorescence microscopy without any green fluorophore showed absolutely no nonspecific imaging in the green channel due to cross-over of the CMTMR-label (Fig. 3A) .
Similarly, negative control images with an isotype control primary antibody showed no colocalization signal (Fig. 3B) . Immunofluorescence imaging of an uninjured lung without BMC treatment shows airway localization of CCSP ( Fig. 3C ) with no non-specific staining of the airway epithelium in the isotype control. However, some CMTMR-positive cells which also expressed the pulmonary epithelial marker CCSP were observed in the injured, cell-treated animals ( Fig. 3D) . To rule out overlapping cells causing apparent co-localization, confocal microscopy was used to provide optical dissection of all possible planar combinations (X-Y, X-Z and Y-Z). Co-localization of the red and green fluorescence in all planar views was counted as a double-positive BMC. Some BMC appeared to express the airway epithelial Clara cell marker, CCSP (Fig. 3E) . Morphologically, in terms of size, orientation and location, the double positive BMC resembled that of airway Clara cells and persisted in the lungs 14 days after cell delivery (Fig. 3F, p<0 .001 compared to Days 1, 4, and 7). As an alternative to the images provided in Figure 3E , another way to visualize confocal microscopy data is as a z-series stack. Optically dissected images of the section along the z-axis clearly demonstrate colocalization of the CMTMR-label with the CCSP stain in one cell (Fig. S2A) , ruling out superimposition of a CMTMR + BMC with a lung cell. Additional representative confocal photomicrographs of other airway-localized CMTMR + BMC expressing CCSP are provided in Supplementary Material (Fig. S2B) .
CMTMR-labeled BMC were also seen in the alveoli and expressed the alveolar Type II epithelial cell marker, proSP-C (Fig. S3A,B) . Few K18 (Fig. S3C, D) or K5/8 (Fig. S3E,F 
BMC found in the lungs express cytokeratin-18 promoter-driven transgene mRNA
Co-localization of fluorescent signals, even with confocal microscopy, is subject to multiple difficulties in interpretation. Therefore, we developed a cell lineage-specific transgenic mouse reporter system to evaluate donor-derived BMC by real-time PCR. Transgenic mice that express GFP under the regulatory control of the human K18 promoter (K18GFP) were created and used as a source of BMC. Cytokeratin-18-driven GFP expression was localized to the surface epithelium of the large (data not shown) and small airways of the lungs (Fig. 5A ) and in isolated TEC (Fig. 5C ) of K18GFP transgenic mice, but not in wild-type lungs (Fig. 5B ) and BMC from K18GFP mice (Fig. 5D ). To confirm epithelial specificity of GFP expression in the transgenic donor mouse, transgene expression was assessed using anti-GFP staining of various tissues. In addition to the pulmonary expression, GFP was detected in the intestinal epithelium but not in the heart or liver of K18GFP mice (Fig. 5E ). In addition, real time PCR was used to assess transgene expression using intron-spanning primers (Fig. 5F ) in isolated TEC, tracheal fibroblasts, fresh and 7-day cultured BMC of K18GFP mice. No transgene expression was detected in any cells except for TEC (Fig 5G) .
These K18GFP BMC were injected into the trachea of wild-type naphthalene-treated animals. The presence of donor-derived BMC was confirmed by analyzing genomic DNA using a primer set designed to initiate amplification within the K18 Intron-1 region and end within the GFP transgene region (Fig. 5F ). No donor DNA was detected in the tracheal or lung tissue isolated from wild-type mice. In contrast, low but detectable donor-derived DNA was found in the lungs (Fig. 6A ) and trachea (data not shown) of wild-type recipient mice receiving K18GFP
BMC. Genomic DNA decreased over time. Donor-derived DNA was also detected in the heart of recipient mice (Fig. S7A ).
To examine K18-driven GFP expression, reverse-transcribed total RNA was assessed using the intron-spanning primer pair. Expression of donor-derived K18GFP mRNA increased over time in the lungs (Fig. 6B ) and trachea (data not shown). K18GFP mRNA expression was not observed in the heart even though levels of genomic DNA was detected (Fig. S7B ).
Anti-GFP staining of recipient lung sections show presence of GFP positive cells in the airways of mice at all time points (Fig 6C) . This data suggested that the plastic-adherent BMC population can initiate transcription of genes generally considered to be specific to epithelium although in vivo several mechanisms, including fusion, might explain this finding. Thus, we analyzed freshly isolated and cultured BMC from K18GFP mice for a panel of epithelial cytokeratin proteins by flow cytometry. As expected, freshly isolated BMC from K18GFP mice were negative for all cytokeratins (Fig 6D) . Anti-GFP staining was negative in the freshly isolated cells. After 7 days in culture, no cytokeratin or GFP positive cells were found however by 28 days in culture a significant percentage of the BMC were positive for all cytokeratins and GFP (Fig. 6D ).
Discussion
In this study, we present a novel concept -selective acute destruction of a cell of interest combined with carefully timed, targeted cell delivery -a concept we have termed "cell replacement therapy". Although the level of donor cell retention was low, this study provides proof of principle that targeted delivery of short-term cultured BMC into a specific but mild and reversible airway injury milieu may favour BMC engraftment. Transtracheal delivery was more efficacious in enhancing BMC retention in the lung than the intravenous route, which not only (25, 26) , strategies need to be developed to increase the percentage of engraftment, but it is clear that significant functional benefit may be achievable with far less than 100% epithelial replacement.
Other reports have suggested that intravenously delivered plastic-adherent BMC can transdifferentiate into lung epithelium using immunofluorescent co-localization of Y- delivery of plastic-adherent BMC cultured for 7 days can engraft in the airway and express cytokeratins and CFTR in a similar naphthalene-induced lung injury model (26) . The frequency of engrafted BMC was less than in our study, perhaps due to our use of transtracheal delivery.
Kotton et al showed intravenous delivery of plastic-adherent BMC can express Type I pneumocyte marker in vitro and engrafted as pneumocytes in vivo in an animal model of pulmonary fibrosis (24). In these studies, BMC engraftment levels were rare to low. Other studies using another lineage-specific reporter (transgenic SPC-EGFP mice in which the fluorescent reporter gene was regulated by the SP-C promoter) reported low or undetectable levels of BMC engraftment in the lung (23). These discrepancies may reflect different models of lung injury, differences between the K18 and SP-C promoters, methods of BMC delivery, or differences in populations of BMC used.
To improve airway engraftment, the mode of BMC delivery for optimal repair and regeneration of injured tissue may be critically important. Engraftment in the airways by the intravascular route is dependent on the ability of these cells to receive and respond to the airway injury signals and migrate out of blood vessels to the injured airways. As expected, we found significantly greater donor BMC in the lungs after transtracheal delivery (10-fold greater than intravenous delivery). Most of the intravenously delivered BMC were found in the alveoli and only rarely were airway-localized cells found. The advantages of direct airway delivery are that cells can be targeted to the airways, reduced systemic delivery of the BMC to other organ systems and reduced requirement for tissue damage to induce BMC homing to the lung. is not be an accurate estimate since the airway epithelium is still undergoing rapid cell turnover and regeneration (36) . We speculate that the total contribution of BMC to the airway epithelium after transtracheal delivery would be at most 1% after complete airway epithelial regeneration.
The total contribution of BMC-derived Type 2 alveolar epithelial cells was 7.5±1.5% with no significant changes in the number of SP-C + CMTMR + cells in the alveoli from day 1 up to day 14 after cell delivery (data not shown). However, since alveolar injury is also seen in this naphthalene injury model (34), we would also speculate that the total contribution of Type 2 alveolar cells from BMC would be less than 6.7±1.8% (at day 14) after complete regeneration of the epithelium. Overall, this data does illustrate that, the total contribution of BMC giving rise to CCSP and SP-C-expressing cells is markedly increased after transtracheal delivery compared to other published reports (26, 27) .
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Our study further validates the possibility of BMC transdifferentiation into lung epithelium by using BMC from transgenic mice that expressed transgene in epithelial lineagecommitted cells. BMC from K18GFP transgenic mice was delivered into wild-type recipients and the K18GFP transgene was progressively upregulated in lungs of recipient wild-type mice.
Plastic-adherent BMC or myofibroblasts from these transgenic mice do not express K18GFP mRNA, suggesting that in vivo detection of K18GFP expression by PCR or anti-GFP immunofluorescence occurred as a result of transdifferentiation of the BMC into K18-expressing cells. K18GFP mRNA was not detected in the hearts of recipients even though transgenic DNA was present. This suggests that the lung milieu may play an important role in dictating epitheliallineage commitment. This is consistent with recent data from MacPherson et al, who also suggest that residence within the lung milieu is required for cytokeratin expression by donor BMC (28).
While cell phagocytosis was seen by FISH, it seems unlikely that macrophage or epithelial phagocytosis (efferocytosis) of BMC (39) could result in such prolonged transgene expression. Although expression of transgene may occur as a result of cell fusion, this is likely a rare and possibly undetectable event in vivo (14) . In vitro, without co-culture with any other cell type, some BMC from K18GFP mice demonstrated detectable GFP expression after longer term culture, proving that BMC-epithelial fusion is not required for expression of K18 promoterdriven gene expression.
Cell proliferation is clearly important for tissue regeneration. We did not observe an increase in donor cell number or genomic DNA over time. This suggests that substantial cell proliferation did not occur, although we speculate that a small population of donor cells may be undergoing low levels of cell division. Therefore, direct assessment of cell proliferation of the retained BMC by conventional BrdU labeling, or staining for proliferation antigens Ki67 and PCNA was not performed. Despite the improved level of BMC retention demonstrated in this study, overall levels clearly are still not sufficient to achieve large-scale tissue regeneration. This study should encourage further efforts to optimize BMC selection and delivery methods.
The recent discoveries that a subset of BMC have immunomodulatory roles is promising for the potential therapeutic use of these cells. Fazel et al (11) and Ayach et al (2) showed that bone marrow stem/progenitor cells are important for cardiac repair and regeneration by promoting angiogenesis and matrix remodeling. Similarly, Ortiz et al (30) and Xu et al (41) showed the immunomodulatory role of MSC in protecting against bleomyocin-induced fibrosis and endotoxin-induced local and systemic inflammation respectively. In both studies, intravenous delivery of MSC provide anti-fibrotic and anti-inflammatory effects after lung injury. Detailed evaluation suggested that these cells need to home to, but not necessarily engraft in, the lung to have protective effect. Our study provides an alternative route of cell delivery targeted to the lung that will enhance cell delivery to the site of injury and possibly may further enhance the immunomodulatory role of BMC.
Conclusion
Transtracheally-delivered short-term cultured BMC remain in the lung after an acute, mild, and reversible airway-specific injury. Importantly, some of these cells persist to at least 120 days and adopt an "epithelial-like" phenotype. With further development and enhancement of targeting strategies to improve airway engraftment, BMC-mediated cell replacement therapy may become a potential therapeutic modality to treat airway diseases such as cystic fibrosis. Table S1 . Naphthalene-induced airway injury does not impair lung function. In vivo measurement of dynamic lung compliance, resistance and conductance were continuously monitored throughout the 20 minute period of mechanical ventilation as described in methods. 
